Core Insights - Protalix BioTherapeutics aims to achieve revenue between $78 million and $83 million by 2026, driven by the approval of Elfabrio for adults with Fabry disease and the advancement of PRX-115 [2] Group 1: Company Developments - The European Commission has approved a dosing regimen of 2 milligrams per kilogram every 4 weeks for Elfabrio, which is targeted at adults with Fabry disease who are stable on enzyme replacement therapy [2]

Financial Data and Key Metrics Changes - For the full year 2025, total revenues from selling goods were $51.8 million, a modest decrease compared to 2024, driven by changes in quantities sold to Chiesi's inventory and a change in average net selling price due to increased commercial patients in Europe [8] - The company recorded a net loss of $6.6 million in 2025 compared to a net income of $2.9 million in 2024, reflecting increased investment in the clinical pipeline [10] - As of December 31, 2025, the company held $30.3 million in cash equivalents and short-term bank deposits, with a projected cash balance of approximately $50 million by early April 2026 [10] Business Line Data and Key Metrics Changes - Revenues from Chiesi are projected to be approximately $33 million-$35 million in 2026, representing growth of more than 50% [11] - Revenues from Elelyso are expected to be approximately $20 million-$23 million in 2026 [11] - Revenues from license and R&D services increased to $0.9 million, mainly related to agreements with Chiesi [8] Market Data and Key Metrics Changes - The Fabry market is projected to reach approximately $3.4 billion by 2030, with Elfabrio's differentiated profile enhancing its competitive positioning [5] - The approval of the every four weeks regimen in Europe is expected to significantly enhance Elfabrio's market uptake [5] Company Strategy and Development Direction - The company aims to advance its clinical pipeline, including PRX-115 and PRX-119, while maintaining a strong financial position to support these initiatives [12] - The company is focused on expanding its renal pipeline and expects to provide updates on specific indications and mechanisms of action in the coming months [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's financial flexibility and growth trajectory, projecting revenue growth in 2026 of greater than 50% [12] - The approval of the every four weeks regimen in Europe is seen as a significant competitive edge, with expectations for accelerated approval in the U.S. [17] Other Important Information - The company anticipates top-line results from the PRX-115 RELEASE study in the second half of 2027 [6] - The company is expanding its renal pipeline through collaborations and new candidates [7] Q&A Session Summary Question: Insights on marketing initiatives for Elfabrio in the U.S. and sales trajectory in Europe - Management highlighted ongoing promotional activities by Chiesi, including patient ambassador programs, and noted that the approval of the four-week regimen in Europe is expected to enhance market positioning [16] Question: Positioning of PRX-115 in the gout market - Management discussed the potential competitive advantages of PRX-115, including dosing frequency and safety, and projected a significant market opportunity for uncontrolled gout [18][20] Question: Target indications for PRX-119 and potential commercial opportunities - Management indicated that they are targeting high unmet need renal indications and will provide updates on specific mechanisms of action in the future [22][23] Question: Timeline for rollout of Elfabrio's four-week dosing in Europe - Management stated that availability will vary by country, with expectations for rollout starting in the second half of 2026 [27][30] Question: Physician education efforts accompanying the rollout - Management confirmed that Chiesi is actively engaging with treating physicians and stakeholders to promote the new regimen [31]

Financial Data and Key Metrics Changes - For the full year 2025, total revenues from selling goods were $51.8 million, a modest decrease compared to 2024, driven by changes in quantities sold to Chiesi's inventory and a change in average net selling price due to increased commercial patients in Europe [8] - The company recorded a net loss of $6.6 million in 2025 compared to a net income of $2.9 million in 2024, reflecting increased investment in the clinical pipeline [10] - As of December 31, 2025, the company held $30.3 million in cash equivalents and short-term bank deposits, with a projected cash balance of approximately $50 million by early April 2026 [10] Business Line Data and Key Metrics Changes - Revenues from Chiesi are projected to be approximately $33 million-$35 million in 2026, representing growth of more than 50% [10] - Revenues from Elelyso are expected to be approximately $20 million-$23 million in 2026 [10] - Revenues from license and R&D services increased to $0.9 million, mainly related to agreements with Chiesi [8] Market Data and Key Metrics Changes - The Fabry market is projected to reach approximately $3.4 billion by 2030, with Elfabrio's differentiated profile enhancing its competitive positioning [6] - The approval of the every four weeks dosing regimen in Europe is expected to significantly enhance Elfabrio's market position [5] Company Strategy and Development Direction - The company aims to execute its strategy comfortably, including clinical trials, supported by a strong cash position and projected revenue growth [4][12] - The company is advancing its pipeline with PRX-115 for uncontrolled gout and PRX-119 for renal conditions, targeting high unmet needs [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the Fabry market and the potential for Elfabrio to capture a significant market share [5][12] - The company anticipates a productive 2026, driven by a growing number of patients on Elfabrio and a strong financial position [12] Other Important Information - The European Commission approved the 2 mg/kg every four weeks dosing regimen for Elfabrio, which is expected to enhance long-term management for patients with Fabry disease [3][4] - The company expects to continue increasing R&D investment as its clinical programs advance [9] Q&A Session Summary Question: Insights on marketing initiatives for Elfabrio in the U.S. and the impact of the new dosing regimen in Europe - Management highlighted that Chiesi is implementing various promotional activities to increase patient numbers and that the new dosing regimen provides a competitive edge [15][17] Question: Positioning of PRX-115 in the gout market - Management discussed the potential competitive advantages of PRX-115, including improved dosing frequency and safety, and projected a significant market opportunity for uncontrolled gout [18][22] Question: Target indications for PRX-119 and potential commercial opportunities - Management indicated that they are targeting high unmet need renal conditions and will provide updates on specific indications in the future [23][24] Question: Timeline for rollout of the four-week dosing regimen for Elfabrio in Europe - Management stated that the rollout will vary by country, with expectations for effects to start in the second half of 2026 [27][31]

Financial Data and Key Metrics Changes - For the full year 2025, total revenues from selling goods were $51.8 million, a modest decrease compared to 2024, driven by changes in quantities sold to Chiesi's inventory and a change in average net selling price due to increased commercial patients in Europe [8] - The company recorded a net loss of $6.6 million in 2025 compared to a net income of $2.9 million in 2024, reflecting increased investment in the clinical pipeline [10] - Cash equivalents and short-term bank deposits as of December 31, 2025, were $30.3 million, with a projected cash balance of approximately $50 million by early April 2026 due to a $25 million milestone payment [10] Business Line Data and Key Metrics Changes - Revenues from Chiesi are projected to be approximately $33 million-$35 million in 2026, representing growth of more than 50% [11] - Revenues from Elelyso are expected to be approximately $20 million-$23 million in 2026 [11] - Revenues from license and R&D services increased to $0.9 million, mainly related to agreements with Chiesi [8] Market Data and Key Metrics Changes - The Fabry market is projected to reach approximately $3.4 billion by 2030, with Elfabrio's differentiated profile enhancing its competitive positioning [5] - The company anticipates that the approval of the every four weeks regimen in Europe will significantly enhance Elfabrio's market uptake [5] Company Strategy and Development Direction - The company is focused on advancing its clinical pipeline, including PRX-115 for uncontrolled gout and PRX-119 for renal conditions, with expectations of significant market opportunities [5][6] - The company aims to solidify its revenue mix towards Chiesi, which represents the majority of long-term revenue opportunities [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 with strong business flexibility and a growing commercial foundation through partners [12] - The projected revenue growth in 2026 of greater than 50% is attributed to the increasing number of patients on Elfabrio [12] Other Important Information - The company is expanding its renal pipeline through collaborations and expects to provide updates on specific indications by the end of Q2 [24] - The approval of the every four weeks regimen in Europe is expected to enhance the competitive edge of Elfabrio [17] Q&A Session Summary Question: Insights on marketing initiatives for Elfabrio in the U.S. - Management noted that Chiesi is implementing various promotional activities, including patient ambassador programs, to increase market uptake [16] Question: Positioning of PRX-115 in the gout market - Management highlighted that PRX-115 could offer significant differentiation in dosing frequency and potential safety advantages, targeting a market expected to exceed $2 billion [20] Question: Timeline for rollout of Elfabrio's four-week dosing in Europe - Management indicated that availability will vary by country, with expectations for some markets to see rollout in the second half of 2026 [30]

Regulatory Approvals - The European Commission approved Johnson & Johnson's AKEEGA for metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations, marking its second approval in the EU [2] - Protalix BioTherapeutics received approval for a new dosing regimen of Elfabrio, allowing for 2 mg/kg every four weeks for adults with Fabry disease [5] - Incyte's Zynyz received a second indication for the first-line treatment of advanced squamous cell carcinoma of the anal canal [10] Clinical Trial Results - AKEEGA demonstrated a clinically meaningful delay in disease progression in the phase 3 AMPLITUDE trial, nearly halving the risk of progression or death compared to standard care [3] Product Details - AKEEGA was initially approved in April 2023 for metastatic castration-resistant prostate cancer (mCRPC) and is also approved in the U.S. for BRCA2-mutated metastatic castration-sensitive prostate cancer [4] - Elfabrio was originally approved in May 2023 with a dosing regimen of 1 mg/kg every two weeks [7] - Zynyz generated net product revenue of $66 million in 2025, a significant increase from $3.19 million in 2024 [12]

Summary of Idorsia's Conference Call Company Overview - **Company**: Idorsia - **Key Products**: - QUVIVIQ: A dual orexin receptor antagonist for insomnia - TRYVIO (also known as JERAYGO): An endothelin receptor antagonist for systemic hypertension - **Pipeline**: Built on the legacy of Actelion, with a focus on drug discovery and development Financial Position - **Debt Restructuring**: Successfully restructured debt situation, leading to an unencumbered equity story for Idorsia [3] - **Sales Performance**: - QUVIVIQ sales in 2025 reached CHF 134 million, outperforming the guidance of CHF 130 million [6] - Outlook for 2026 sales is around CHF 200 million [6] QUVIVIQ Insights - **Geographic Performance**: - Strong growth in Europe and Canada, with a focus on reimbursement strategies [5] - Notable uptake in Japan, where DORA class accounts for 37% of the insomnia market [4] - In China, 300,000-400,000 patients on QUVIVIQ within the first six months of launch [4] - **Market Strategy**: - Focus on neurologists and psychiatrists initially, followed by general practitioners (GPs) for broader adoption [8] - Co-promotion partnerships in Europe to enhance market access [8] U.S. Market Challenges - **Scheduling Issues**: QUVIVIQ is the third DORA approved by the FDA, facing scheduling challenges due to historical precedents [9][10] - **Citizen Petition**: Submitted to the FDA in April 2023 to address scheduling concerns based on global usage data showing no abuse potential [11][12] Pediatric Data - **Pediatric Program**: Phase 2 dose-finding study for pediatric insomnia expected to report results in Q1 or Q2 2024 [14] - **Potential Impact**: Positive outcomes could support descheduling efforts and improve access for children with sleep disorders [16] Lucerastat for Fabry Disease - **Product Overview**: Oral substrate reduction therapy with advantages over enzyme replacement therapies [17] - **Clinical Development**: Pivotal trial design includes a renal function study based on eGFR [18] - **Market Position**: Positioned as a broadly applicable treatment for Fabry disease, with potential expansion into other lysosomal storage diseases [19] TRYVIO (JERAYGO) Updates - **Approval Status**: Approved in the U.S. and Europe for systemic hypertension [27] - **Differentiation**: Unique profile with no signals for hyperkalemia or hyponatremia, applicable to patients inadequately controlled on other therapies [27][28] - **Partnership Strategy**: Seeking partnerships to maximize value, particularly in cardiology and nephrology [30][31] Pipeline Developments - **CCR6 Antagonist**: Initiated proof of concept study in psoriasis, with potential for expansion into other T helper 17 mediated diseases [34][35] - **CXCR7 for Progressive MS**: Trial initiation expected soon, focusing on anti-inflammatory and remyelinating benefits [36] - **CXCR3 for Vitiligo**: Aiming to disrupt melanocyte targeting, with plans to initiate trials later this year [41][42] Conclusion - **Overall Strategy**: Idorsia is focused on leveraging its unique product offerings and pipeline to create value, while navigating financial challenges and market dynamics [44]

Core Viewpoint - Protalix BioTherapeutics is focused on advancing its innovative pipeline for rare diseases, particularly targeting uncontrolled gout and rare kidney diseases, while maintaining a profitable commercial business through strategic partnerships [2][14]. Pipeline and Product Development - The company is advancing PRX-115 for uncontrolled gout, which has shown a rapid and durable urate-lowering effect in Phase 1 trials, indicating its potential as a differentiated treatment option [3][15]. - PRX-119 is being developed as a long-acting DNase I for treating inflammation and fibrosis in rare kidney diseases, reflecting the company's strategic focus on this area [4][13]. - The company has submitted an Investigational New Drug (IND) application for PRX-115, which has been approved by the FDA, and the first clinical sites are now activated [15]. Commercial Execution and Market Positioning - Protalix has achieved solid performance with its partner Chiesi Global Rare Diseases, particularly with the launch of Elfabrio for Fabry disease, tracking well against core indicators such as treated patient counts and market share [6][7]. - The global Fabry market is projected to reach approximately $3.4 billion by 2030, with Protalix expecting Elfabrio to capture 15% to 20% of this market [7]. - An appeal regarding a negative opinion from the European Medicines Agency on Elfabrio's dosing regimen is underway, with an outcome expected in Q1 2026 [8]. Strategic Partnerships and Collaborations - The company continues to benefit from established revenue streams, including Elelyso, through collaborations with Pfizer and Fundação Oswaldo Cruz, which support its operational resilience [9]. - A recent collaboration with Secarna Pharmaceuticals aims to develop novel therapeutic candidates for rare renal indications using AI technology [15]. Long-Term Growth and Value Creation - Protalix enters 2026 with a profitable commercial foundation and a focused pipeline addressing high unmet medical needs, aiming to create long-term value for patients and shareholders [14]. - The company emphasizes its commitment to delivering meaningful therapies while pursuing strategic partnerships to enhance its impact and scale [5][14].

Core Insights - Protalix BioTherapeutics and Secarna Pharmaceuticals have entered into a collaboration and option agreement to develop antisense oligonucleotide therapies for rare renal diseases, leveraging Protalix's expertise in rare diseases and Secarna's AI-powered OligoCreator platform [1][2][3] Company Overview - Protalix BioTherapeutics focuses on innovative therapeutics for rare diseases and has developed two enzyme replacement therapies available in multiple markets, utilizing a proprietary plant cell-based expression system called ProCellEx [4][5] - Secarna Pharmaceuticals specializes in oligonucleotide therapeutics and employs its OligoCreator platform to rapidly generate high-quality antisense candidates, aiming to transform untreatable conditions into treatable ones [7] Collaboration Details - The collaboration involves Protalix selecting pharmaceutical targets for rare renal indications, while Secarna will use its OligoCreator platform to design and profile ASO candidates against these targets [2] - Protalix has the option for an exclusive, worldwide license to further develop and commercialize the therapeutic programs resulting from this collaboration [2][3] Strategic Goals - The partnership aims to advance programs from preclinical stages to clinical trials, addressing significant unmet medical needs in the rare kidney disease space [2][3] - Both companies express excitement about the collaboration, highlighting the combination of Secarna's rapid candidate generation and Protalix's experience in bringing therapies to market [3]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Company Overview - Protalix BioTherapeutics, Inc. is a New Jersey-based biopharmaceutical company specializing in recombinant therapeutic proteins [4] - The company develops innovative plant-based biologics, including products like Elelyso, Elfabrio, PRX-115, and PRX-119 [4] Investment Activity - Goldman Sachs Group Inc. increased its holdings in Protalix BioTherapeutics by 482.3% during the first quarter, acquiring 239,751 shares, bringing its total ownership to 289,461 shares valued at approximately $741,000 [1] Product Development - Protalix is expanding its ProCellEx platform into drug delivery optimization, targeting specific tissue requirements, which is considered a "game-changer" for the company [3] - The ProCellEx platform is noted for its cost efficiency and ability to express complex protein capabilities, positioning it as a leader in future biopharmaceutical developments [3] Market Position - The company is recognized as a hidden penny stock with potential for growth, likened to planting a tree that requires time and patience to flourish [2]